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ABSTRACT 
  
The Role of ERp57 in Hras Intracellular Trafficking and Function 
by 
Jaime Parman 
Ras is a central player in signal transduction that mediates cellular proliferation and 
differentiation.  Recent evidence has shown that lipid and non-lipid modified domains 
participate in Ras traffic and that plasma membrane association is mediated by vectorial 
vesicular transport from the endomembrane system.  ERp57, an ER chaperone, has been 
shown to specifically bind farnesylated Hras but not non-farnesylated Hras. The objective of 
this study was to determine if ERp57 participates in Ras trafficking and function.  First, the 
effect of ERp57 knock down by siRNA technology on Hras function was studied; there was a 
reduction in ERp57 cellular levels that led to a decrease of active ras.  Second, specific anti-
ERp57 antibodies were delivered into 3T3 cells expressing GFP-ras chimeras to observe the 
effect on intracellular trafficking. Anti-ERp57 antibodies blocked Hras plasma membrane 
localization but not Kras suggesting that ERp57 may be involved in Hras intracellular 
trafficking and function. 
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CHAPTER 1 
INTRODUCTION 
 
   Ras is a monomeric GTP-binding protein that is a member of the G-protein 
superfamily.  Ras serves as a molecular switch that alternates between the active form bound 
with GTP and the inactive form bound with GDP.  Mutations that constitutively activate ras 
proteins have been detected in 30% of all human cancers (Sinensky 2000a).  The ras family of 
proteins is a central player in the transduction of signals that mediate cellular proliferation and 
differentiation.  Ras mitogenic signal transduction has been implicated in many cancers, due to 
either a direct mutation of the ras protein, or the loss of functioning GTPase activating proteins 
(GAP), which terminate the signaling of active ras.     
There are 3 major isoforms of ras, Hras, Nras, and Kras4B.  All 3 isoforms have a 90% 
sequence homology.  Hras, Nras, and Kras contain highly conserved domains that interact with 
effectors, exchange factors, and guanine-nucleotides.  The area in which the isoforms differ 
greatly is the hypervariable region, which includes the last 23-25 carboxy-terminal amino acid 
residues of the protein.   The hypervariable region contains the signal sequences that are required 
for ras plasma membrane localization.  There are 2 domains of the hypervariable region, the 
linker domain and the membrane-targeting domain.  The membrane-targeting domain contains 
the two signal sequences that cooperate in targeting ras to the plasma membrane (Prior and 
Hancock 2001).  The first signal sequence is the same for all 3 isoforms of ras, which is 
prenylation, the sequential post-translational modification of the CAAX box.  The second signal 
sequence in Hras and Nras is the palmitoylation of cysteines and a polybasic domain in Kras 
(Figure 1).  There is evidence that the linker domain contains plasma membrane targeting 
information (Prior et al. 2001).  The linker domain also regulates the interaction of Hras with 
lipid rafts in the plasma membrane and plays a role in regulating the interactions with effector 
proteins (Jaumot et al. 2002).    
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Figure 1: Ras Hypervariable Regions.  Reprinted from Prior IA, Hancock JF.  
Compartmentalization of Ras proteins.  J Cell Sci. 2001 May; 114(Pt 9): 1603-8.  
 
 
Plasma membrane localization is essential for the biological activity of ras (Willumsen et al. 
1984).  Therefore, the mechanism of ras plasma membrane localization has attracted 
considerable attention.  The details of ras intracellular trafficking to the plasma membrane are 
not entirely understood.  However, a model for ras trafficking has been proposed and is 
supported by compelling data (Figure 2)(Apolloni et al. 2000).   
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Figure 2:  Model of Ras Trafficking.  Adapted from Apolloni A, Prior IA, Lindsay M, Parton 
RG, Hancock JF.  H-ras but not K-ras traffics to the plasma membrane through the exocytic 
pathway.  Mol Cell Biol. 2000 Apr; 20(7): 2475-87.  
 
 
As mentioned previously, there are 2 signal sequences that are required and must cooperate for 
plasma membrane localization of ras.  The first signal, the CAAX box (C=cysteine, A=aliphatic 
amino acid, X=serine or methionine) is common to all 3 forms of ras and is located at the C-
terminus.  The CAAX box is sequentially modified, as the cysteine is farnesylated by an enzyme 
known as farnesyltransferase (Reiss et al. 1990).  Ras then travels to the cytosolic side of the 
endoplasmic reticulum (ER) where an endoprotease, RCE1, cleaves AAX, the last 3 residues 
from the ras protein, leaving the farnesylated cysteine at the C-terminus (Boyartchuk et al. 1997).   
The C-terminal cysteine is then carboxymethylated by a prenylcysteine 
carboxymethyltransferase (pcCMT) (Dai et al. 1998).  The processed CAAX box must now act 
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in conjunction with a second signal to target ras to the plasma membrane (Choy et al. 1999; 
Apolloni et al. 2000; Hancock 1990).  Kras is thought to leave this trafficking pathway at this 
point because it contains a polybasic domain, a stretch of 6 lysines (175-180), in the 
hypervariable region, as its second signal (Hancock 1990).  Hras and Nras are further modified 
to produce the second signal, the palmitoylation of cysteine 181 in Nras or cysteines 181 and 184 
in Hras, which are found in the hypervariable region of the protein (Hancock 1990).   Hras and 
Nras then enter the secretory pathway by trafficking through the Golgi to the plasma membrane 
(Choy et al. 1999; Apolloni et al. 2000), whereas, Kras bypasses the Golgi and traffics to the 
plasma membrane through an unidentified pathway (Apolloni et al. 2000).  Since the CAAX-
processing enzymes are all ER residents (Dai et al. 1998) and recent data suggest that 
palmitoylation occurs at the ER (Choy et al. 1999), the final processing of the CAAX box must 
occur on the cytosolic face of the ER membranes.  However, this raises the question of how 
trafficking of ras proteins from the ER to the plasma membrane occurs after the post-
translational modifications.  Recent studies, using green fluorescent protein (GFP) fused to ras 
protein creating Ras-GFP chimeras have shown that Nras and Hras are found throughout the 
secretory pathway (Choy et al. 1999; Apolloni et al. 2000).  To test whether GFP-Nras and GFP-
Hras use vesicular transport to access the plasma membrane experiments were conducted using 
Brefeldin A, a drug that disassembles the Golgi apparatus.  The results of these experiments 
revealed a pronounced accumulation of these proteins in the ER (Choy et al. 1999; Apolloni et 
al. 2000), indicating that vesicular transport is required for plasma membrane localization of 
Hras and Nras.  A 15°C temperature block, which impairs transport from the ER to the Golgi, 
was also used to compare the trafficking of Hras and Kras (Choy et al. 1999).  These results 
demonstrated an accumulation of Hras in the intermediate compartment between the ER and the 
10 
Golgi.  In contrast, however, there was no accumulation of Kras, presumably due to the 
polybasic domain excluding Kras from the Golgi (Apolloni et al. 2000).  Because the 
temperature block or treatment with Brefeldin A did not affect the trafficking of Kras to the 
plasma membrane, it can be concluded that palmitoylated Hras and Nras proteins use vesicular 
trafficking through the secretory pathway to access the plasma membrane, whereas Kras does not 
(Choy et al. 1999; Apolloni et al. 2000).  Although Hras and Nras use vesicular transport to 
access the plasma membrane, they are not traditionally packaged on the inside of the vesicles; 
instead, Hras and Nras must be transported on the cytoplasmic face of the transport vesicles 
(Choy et al. 1999). This is where the differential role of the second signal (palmitoylation or a 
polybasic domain) may become critical in signaling release from the ER compartment (Apolloni 
et al. 2000). 
Recent evidence of the role of the carboxy-terminal amino acids of Hras in plasma 
membrane localization shows that both lipid-modified and non-lipid-modified domains play a 
role in Hras movement throughout the cell and plasma membrane association (Sinensky 2000a).  
In addition, Choy et al. discovered that the C-terminus CAAX box is sufficient to target proteins 
to the endomembrane system and that localization to the plasma membrane requires a second 
signal (Choy et al. 1999).  Given that plasma membrane localization of Hras is mediated by 
vesicular transport suggests that prenylated cytosolic Hras interacts with specific proteins in the 
endomembrane system, which makes Hras accessible for further processing.  Because the plasma 
membrane is the ultimate destination of Hras, it has been hypothesized that there is a protein that 
recognizes both the plasma membrane and the farnesylation of Hras (Rusinol et al. manuscript 
under revision).  Evidence to support this hypothesis for the existence of such a protein has been 
presented by Siddiqui et al. (1998).  Siddiqui et al. proposed the “two-site” hypothesis where 
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partner proteins specifically bind to prenylated proteins through the recognition of both the lipid 
substituents and the primary sequence of the prenylated protein partner.  Previous work by 
Rusinol et al. (manuscript under revision) used a combination of ion exchange and affinity 
chromatography to identify a prenylation-dependent Hras binding protein, which was confirmed 
by ligand blotting (Rusinol et al. manuscript under revision).  A 58kDa band was observed as 
having the highest binding activity to farnesylated Hras.  This 58kDA band showed nearly a 
100% sequence homology with a previously cloned protein, which has been identified by 
multiple laboratories (Mazzarella et al. 1994; Bourdi et al. 1995,).  This protein has been given 
multiple names, P58, ER60, Grp58, and ERp57, Rusinol et al. refers to this protein as ERp57 as 
will I (Rusinol et al. manuscript under revision).  Bourdi et al. isolated the human clone of 
ERp57 (1995).  ERp57 is a member of the protein disulfide isomerase (PDI) family of enzymes.  
ERp57 is found mostly in the ER, but recent evidence has indicated that it is also present in the 
cytosol, plasma membrane and nucleus (Johnson et al. 1992; Guo et al. 2002; Coppari et al. 
2002).  PDI, the best-known member of the family, and ERp57 have been shown to be involved 
in the proper folding and formation of disulfide bonds of proteins that are synthesized in the 
rough ER.  They also function as chaperones and redox-catalysts, which are essential for cell 
viability (Turano et al. 2002, Coppari et al. 2002).  Rusinol et al. (2003) has shown that ERp57 
specifically binds to farnesylated Hras but not non-farnesylated Hras.  In this study ERp57 has 
been described as a functional partner for Hras, which is consistent with the “two-site” 
hypothesis.  The objective of the present investigation was to test the hypothesis that ERp57 
participates in Hras trafficking to the plasma membrane and therefore is necessary for Hras 
function.  Primarily two approaches were used to test this hypothesis.  The first approach was to 
study the effect of an ERp57 knock down by siRNA technology on Hras function.  In this 
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system, the reduction of ERp57 cellular levels led to a decrease of GTP-bound ras as shown by 
interaction with raf1.  The second approach was to deliver specific anti-ERp57 antibodies into 
live 3T3 cells expressing GFP chimeras with ras and control proteins and then observe the effect 
on intracellular trafficking.  In this system, anti-ERp57 antibodies blocked Hras localization to 
the plasma membrane but not Kras, suggesting that ERp57 may be involved in Hras intracellular 
trafficking and function.      
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CHAPTER 2 
MATERIALS AND METHODS 
 
Plasmids 
pEGFP was from Clontech; Kras-GFP was a gift from Dr. Patrick Casey, Duke 
University.  Hras-GFP fusion protein was created from Hras in pSP64 (Promega, Madison, WI) 
by cutting with HindIII, which gives 2 fragments.  The larger of the 2 fragments (3.6Kb) was gel 
purified using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA).  Digestion of the 3.6Kb 
fragment with restriction enzyme BamHI gave 2 fragments in agarose gel electrophoresis, a 
686bp and a 2.3Kb fragment.  The 686bp fragment (ras) was gel purified and directionally 
ligated into the vector pEGFP-C3 (Clontech, Palo Alto, CA) to yield the finished construct, 
which was confirmed by restriction enzyme analysis.          
DNA and Protein Transfections 
DNA transfections were done by using GeneJammer from Stratagene (La Jolla, CA).  
Protein transfections were done using ProJect from Pierce (Rockford, IL) or Bioproter from 
Sigma (St. Louis, MO).  All transfections were performed according to manufacturer’s 
instructions. 
Electrophoresis and Transfer to PVDF Membranes 
One-dimensional SDS-PAGE was performed under reducing conditions on a 4-
12%gradient Bis-Tris NuPAGE precast slab gel from Invitrogen (Carlsbad, CA).  
Electrophoresis was performed at 200 volts for 45 minutes using the Novex Shurelock System 
from Invitrogen.  Broad range pre-stained protein markers from Invitrogen were used to estimate 
the relative molecular masses of the proteins.  Electrophoretic transfer to PVDF membranes 
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(Millipore) was performed in 20mM Tris-HCL and 0.15M glycine 10% methanol buffer, pH 8.1, 
for 60 minutes at 60 volts. 
Western Blot 
After transfer to PVDF, membranes were blocked for 1 hour in 5% nonfat milk in tris-
buffered saline containing 0.1%Tween 20 (TBS-T).  PVDF membranes were then probed with 
antibodies.  Membranes were incubated with primary antibody; diluted 1:1000 in 5% nonfat milk 
in TBS-T solution, either anti-ERp57 (Stressgen, Victoria, BC), anti-Hras (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-Kras (Calbiochem, San Diego, CA) or anti-Pan-ras 
(Oncogene, San Diego, CA), for 1 hour and washed 3 times for 5 minutes each.  After 
washing, membranes were then incubated with secondary antibody; diluted 1:25000 in 5% 
nonfat milk in TBS-T solution, either goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, 
Santa Cruz, CA) or goat anti-mouse IgG-HRP (Pierce, Rockford, IL), for 1 hour and washed as 
before.  Antibody-bound proteins were detected by chemiluminescence from Pierce. The 
membranes were then exposed to X-ray film to visualize the proteins. 
Immunofluorescence 
3T3 cells were grown on glass coverslips overnight.  After washing with PBS, cells were 
fixed in freshly prepared 4% paraformaldehyde in PBS, pH 7.3.  After fixation, cells were 
incubated for 1 hour with anti-human ERp57 specific rabbit polyclonal antibodies (Stressgen, 
Victoria, BC), diluted 1:100 in 5% BSA in PBS, rinsed 3 times with PBS, and then stained for 1 
hour with FITC-conjugated anti-rabbit IgG or Texas Red-conjugated anti-rabbit IgG (Stressgen, 
Victoria, BC), diluted 1:500 in 5% BSA in PBS.  For co-localization experiments, cells were also 
incubated with mouse monoclonal anti-PMCA ATPase antibodies (Affinity BioReagents, 
Golden, CO) and Texas Red- conjugated anti-mouse IgG (Stressgen, Victoria, BC).  Cells were 
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then mounted in a special medium for fluorescence (Prolong Anti-fade, Molecular Probes) and 
observed.  Confocal images were obtained by digital deconvolution of 10-slice stacks acquired 
on a Nikon Diaphot 200 equipped with a Photometrics Sensys cooled CCD digital camera or 
Nikon D100, Oncor Z-drive and Oncor image software. 
Co-immunoprecipitations 
Co-immunoprecipitation assays were performed using Seize Coated Plate 
immunoprecipitation Kits from Pierce (Rockford, IL) according to manufacturer’s instructions.  
3T3 cells were grown briefly in DMEM 10% FBS medium and then scraped and solubilized in a 
buffer containing Triton X-100 to a protein concentration of 1mg/ml.  Cell lysates were then 
incubated with primary antibodies, either anti-Hras or anti-Kras, immobilized onto 96-well plates 
coated with protein A/G.  After binding, washing, and elution, the co-presence of ras and ERp57 
in the precipitates was examined by immunoblotting. 
VSVG Intracellular Trafficking 
Dr. Jennifer Lippincott-Schwartz (National Institutes of Health, Bethesda, MD) kindly 
provided a vector expressing a temperature sensitive VSVG-GFP chimera (Presley et al. 1997).  
3T3 cells were transiently transfected with VSVG-GFP and cultured at 40°C.  After 16 hours at 
40°C, cells were transfected with anti-ERp57 antiserum and incubated for 6 hours, then switched 
to 32°C for 3 hours.  VSVG-GFP localization was then determined by fluorescence microscopy 
and digital deconvolution as described previously. 
siRNA Construction and Transfections 
pSilencer from Ambion (Austin, TX) was used in siRNA experiments.  Target sites for 
siRNA in ERp57 were selected using Ambion’s siRNA target finder and design tool that follows 
the current guidelines for siRNA design.  Based on the target sequences, 5 complementary 
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oligonucleotide pairs (4 with correct sequences plus 1 randomized sequence) were custom 
synthesized.  The oligos were then allowed to anneal, creating ApaI and EcoRI overhangs.  
siRNA generating vectors were constructed by ligating the annealed oligos into linearized 
pSilencer vector.  The finished siRNA plasmid was transfected into 3T3 cells as described above. 
Detection of Ras Activation 
Active ras in 3T3 cell lysates was detected using the EZ-Detect Ras Activation Kit 
from Pierce (Rockford, IL).  Cell lysates were treated according to manufacturer’s instructions.  
Then the pulled-down active ras was detected by Western Blot using anti-ras antibody.  
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CHAPTER 3 
RESULTS 
 Previous experiments by Rusinol et al. used HeLa cells in ERp57 localization 
experiments.  The Ras-GFP chimeras that were used in this study are stably expressed in 3T3 
cells, because 3T3 cells are larger and allow for easier observation of intracellular trafficking.  
Therefore, it was necessary to determine where ERp57 localizes in 3T3 cells.  This was 
determined by standard immunofluorescence, which is explained in materials and methods.  The 
results show that ERp57 is localized mostly in the ER but is also present in the plasma 
membrane of 3T3 cells as indicated by the arrows in figure 3.   
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Figure 3:  Detection of ERp57 in 3T3 Cells.  A representative cell of several experiments is 
shown.  Localization of ERp57 was observed mostly in the ER but is also seen in the plasma 
membrane of 3T3 cells as indicated by the arrows. 
 
To confirm that ERp57 was in fact localized in the plasma membrane, a co-localization 
experiment was performed as a control, using an anti-PMCA ATPase antibody as a plasma 
membrane marker.  Figure 4 shows the results of the co-localization between ERp57 and the 
calcium pump of the plasma membrane (PMCA ATPase) in 3T3 cells.  PMCA-ATPase showed 
a typical plasma membrane staining whereas ERp57 showed a cytoplasmic distribution (mostly 
ER) but also showed plasma membrane staining which is seen with the co-localization of 
PMCA-ATPase in many areas.  These results are consistent with partial ERp57 localization to 
the plasma membrane as previously reported in other cell types (Wyse et al. 2001; Guo et al. 
2002) as well as the isolation of ERp57 from our purified plasma membrane preparations 
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(Rusinol et al. manuscript under revision).  Since trafficking of Hras begins in the ER and 
terminates in the plasma membrane, the co-localization of ERp57 at the plasma membrane is 
consistent with the hypothesis that ERp57 plays a role in Hras trafficking.   
 
 
 
 
 
 
 
 
 
 
Figure 4: Subcellular Localization of ERp57 in 3T3 Cells. The subcellular distributions of 
ERp57 and plasma membrane calcium ATPase (PMCA-ATPase) were determined in 3T3 cells 
by indirect immunofluorescence as described in Materials and Methods. Cells were visualized by 
fluorescence microscopy and digital deconvolution. Images represent single digitally 
deconvolved sections. Shown is a representative cell of several experiments.  The panel on the 
right is an overlay of the ERp57 and PMCA ATPase images and shows numerous areas of co-
localization in the plasma membrane (yellow).  
 
 
10µm 10µm 10µm
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Data from Rusinol et al. have shown that ERp57 and Hras interact in vitro, but not in 
vivo (Rusinol et al. manuscript under revision).  To determine if ERp57 is able to associate with 
Hras in vivo, co-immunoprecipitation experiments were performed.  As described in materials 
and methods, 3T3 cells were solubilized in Triton-X100 buffer and centrifuged to remove the 
insoluble fraction.  The cell lysate (soluble fraction) was immunoprecipitated with monoclonal 
anti-Hras and anti-Kras antibodies.  The immunoprecipitates were then analyzed by 
immunoblotting for the presence of Hras, Kras and ERp57.  Figure 5 shows that the anti-Hras 
antibodies immunoprecipitated Hras and ERp57 (Figure 5A) and that the anti-Kras antibodies 
immunoprecipitated Kras but not ERp57 (Figure 5B).  The specificity of this reaction was 
confirmed by showing that the anti-ras antibodies did not precipitate other molecular chaperones, 
such as GRP94 and PDI (Figure 5C).  
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Co-immunoprecipitation of ERp57 and Ras.  3T3 lysates were immunoprecipitated 
with rabbit polyclonal anti-Hras (A) rabbit polyclonal anti-Kras (B) or mouse monoclonal anti-
pan-ras antibodies (C).  A) The immunoprecipitates from anti-Hras antibodies were separated by 
SDS-PAGE, blotted, and probed with rabbit anti-Hras and rabbit anti-ERp57 antibodies.  B) The 
immunoprecipitates from anti-Kras antibodies were probed with rabbit anti-Kras and rabbit anti-
ERp57 antibodies. A control lane in which anti-ras antibodies were omitted showed no 
detectable ERp57.  TCL: positive control with equivalent amount of total cell lysate loaded on 
the gel.  NR: TCL after immunoprecipitation with a pre-immune antibody.  Anti-H: TCL after 
immunoprecipitation with anti-Hras antibodies.  Anti-K: TCL after immunoprecipitation with 
anti-Kras antibodies.  IP (A): ERp57 and Hras were immunoprecipitated with anti-Hras 
antibodies.  IP (B): Kras was immunoprecipitated with anti-Kras antibodies, but no ERp57 was 
present.  C) The immunoprecipitates formed by treatment with anti-pan-ras antibodies were 
tested for the presence of other chaperones.  IP: immunoprecipitates were blotted and probed for 
GRp94 and protein disulfide isomerase. TCL: equivalent amount of total cell lysate. 
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Role of ERp57 in Hras Trafficking 
In order to test the hypothesis of the involvement of ERp57 in Hras intracellular 
trafficking and function, we reduced the cellular levels of ERp57 using 2 methods, siRNA 
technology and peptide mediated protein delivery.  siRNA is a technique that is used to reduce 
the expression of a specific gene in living cells by introducing a homologous dsRNA.  Once 
inside the cell, the dsRNAs are cleaved into short 21-25 nucleotide siRNAs.  The siRNAs 
assemble into an RNA-induced silencing complex (RISC) where it is unwound and activated.  
This allows the siRNA antisense strand and mRNA to bind to their complementary transcript by 
base pairing interactions.  Gene silencing is the result of sequence specific cleavage of the 
mRNA-siRNA-RISC complex.  This technology was used to study the functional consequences 
of reducing ERp57 expression.  There are 5 ways to produce siRNAs; we chose to use a siRNA 
expression plasmid, the pSilencer vector from Ambion (Austin, TX).  Target sequences were 
designed to reduce the cellular expression of ERp57.  The knockdown experiments were 
performed by ligating the target sequences into the pSilencer vector then transfecting 3T3 cells 
and 3T3 cells expressing GFP-Hras chimeras with the pSilencer  construct.  The total cell 
expression of ERp57 in the transfected cells was then analyzed by Western blot (Figure 6).  
Figure 6 shows that the cellular levels of ERp57 in 3T3 cells are reduced by siRNA expression 
over time.  The transfected cells were observed by fluorescence microscopy at the different time 
points to observe the effect of reduced ERp57 levels, by siRNA expression, on Hras plasma 
membrane localization.  Figure 7 indicates that the reduction of ERp57 blocks the intracellular 
trafficking of Hras-GFP to the plasma membrane. 
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Figure 6:  ERp57 Levels in 3T3 Cells Are Reduced by siRNA Expression.  Cells were 
transfected with empty pSilencer vector as a control and with the pSilencer-ERp57 siRNA 
construct then lysed at different time points.  Total cells lysates were separated by SDS-PAGE 
and then analyzed by Western Blot using anti-ERp57 antibodies.  The level of ERp57 in 3T3 
cells was drastically reduced, 48 hours after transfection, by siRNA expression, as compared to 
the control where the level of ERp57 is constant. 
 
 
The transfected cells were observed by fluorescence microscopy at the different time points to 
observe the effect of reduced ERp57 levels, by siRNA expression, on Hras plasma membrane 
localization (Figure 7).  Figure 7 indicates that the reduction of ERp57 blocks the intracellular 
trafficking of Hras-GFP to the plasma membrane. 
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Figure 7: Reduction of ERp57 Expression Blocks Hras-GFP Intracellular Trafficking.  3T3 cells 
stably expressing Hras-GFP were transfected with the pSilencer-ERp57 siRNA randomized 
sequence (control) and the pSilencer-ERp57 siRNA construct.  Cells were observed by 
fluorescence microscopy.  Shown is a representative cell of several experiments.  This figure 
shows that 48 hours after transfection, Hras-GFP traffic to the plasma membrane is blocked as 
compared to the control where there is clear plasma membrane localization. 
 
Because the reduced levels of ERp57 had such a dramatic effect on Hras-GFP trafficking to the 
plasma membrane, we examined whether the reduction ERp57 expression had any effect on the 
activation of ras in 3T3 cells.  The EZ-Detect Ras Activation Kit from Pierce (Rockford, IL) 
was used for this experiment.  The kit uses the Ras-binding domain of Raf1, and specifically 
“pulls down” active ras (GTP bound) out of cell lysates.  The proteins that were “pulled down” 
were separated by SDS-PAGE and then analyzed by Western Blot using anti-ras antibodies, 
which is shown in figure 8.  
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Figure 8: Reduction of ERp57 Expression Hinders Ras Activation.  Cells were transfected with 
empty pSilencer vector as the control and the pSilencer-ERp57 siRNA construct.  Cells were 
lysed at different time points then analyzed by Western Blot using anti-ras antibodies.  The 
amount of active ras in the cell lysate was then determined using the Raf-1 binding domain of 
ras.  This figure shows that overtime the amount of active ras in 3T3 cells was decreased due to 
reduction of ERp57 expression. 
  
In the second approach, the ability of ERp57 antibodies to inhibit the trafficking of Hras 
was confirmed in whole cells.  This was done by examining the effect of transfection with 
ERp57 antibodies on the intracellular localization of Hras-GFP chimeras expressed in 3T3 cells.  
ERp57 antibodies were introduced into the cells by a peptide carrier technology (Morris et al. 
2001), in which proteins are delivered into the cytosol of transfected cells.  Figure 9 shows the 
effect of ERp57 antibodies on the intracellular localization of GFP chimeras with full-length 
Hras and an Hras 21a.a. C-terminal fragment (HrasCT).  Control experiments were done by 
transfecting the Hras-GFP or HrasCT-GFP cells with non-immune serum, which shows plasma 
membrane localization as well as cytoplasmic staining (Figure 9A, C).  Our results were 
consistent with previous results reported by Choy et al. for expression of these GFP constructs in 
Control
(72h)
24h 48h 72h
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3T3 cells (Choy et al. 1999).  However, transfection with the ERp57 antibody resulted in the 
accumulation of Hras-GFP in intracellular vesicles, possibly the ER, in both constructs (Figure 
9B, D).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Anti-ERp57 Antibodies Block the Trafficking of Full-length Hras and HrasCT-GFP to 
the Plasma Membrane.  3T3 cells stably expressing full-length Hras-GFP or HrasCT-GFP were 
transfected with anti-ERp57 antibodies.  The location of the GFP chimeras was then assessed by 
fluorescence microscopy followed by digital deconvolution of the acquired images. Shown is a 
representative cell of several experiments.  When cells expressing full-length Hras-GFP (A) or 
HrasCT-GFP (C) were transfected with the protein delivery reagent only, clear plasma 
membrane localization was observed.  When cells were transfected with 2µg/ml of anti-ERp57 
antibodies, traffic of both chimeras to the plasma membrane was completely blocked (B and D).      
A B
C D
control + Anti-ERp57
control + Anti-ERp57
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To examine the specificity of the inhibition of Hras trafficking by ERp57 antibodies, 
relative to another protein that uses the secretory pathway to access the plasma membrane, the 
effect of transfection with ERp57 antibodies on the trafficking of VSVG protein was examined.  
For the studying of this protein, we used a previously reported system (Presley et al. 1997), in 
which a temperature sensitive mutant of VSVG (tsVSVG) was used.  At a nonpermissive 
temperature of 40°C the tsVSVG-GFP is unable to exit the ER (Figure 10A).  However, at the 
permissive temperature of 32°C the tsVSVG-GFP is allowed to traffic using the secretory 
pathway to show clear plasma membrane and Golgi localization (Presley et al. 1997)(Figure 
10C).  The tsVSVG-GFP was transiently expressed in 3T3 cells then transfected with anti-
ERp57 antibody (Figure 10B, D).  Co-transfection with Texas-Red conjugated anti-rabbit IgG 
was used to monitor transfection of the antibody into individual cells.  Texas-Red positive cells 
were then examined for the localization of the green tsVSVG.  The results observed in Figure 10 
show that the cells transfected with anti-ERp57 antibodies and switched to 32 °C had no effect 
on the transport of VSVG-GFP to the plasma membrane (Figure 10D). 
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Figure 10: Anti-ERp57 Antibodies Do Not Affect tsVSVG Traffic to the Plasma Membrane. 3T3 
cells transiently expressing tsVSVG and cultured at 40 °C were transfected with pre-immune 
antiserum (not shown) or antiERp57 antibodies. Texas Red-mouse IgG was also included as a 
marker for transfection (A, C). Cells were incubated for 6h at 40 °C in regular growth medium. 
Cells were then maintained at 40 °C (B), or switched to 32 °C (D). VSVG-GFP traffic to plasma 
membrane was determined in Texas-red positive cells after 3h by fluorescence microscopy. 
Images represent single digitally deconvolved sections.  Shown is a representative cell of several 
experiments.  This experiment indicates that ERp57 antibodies did not block plasma membrane 
localization of tsVSVG at the permissive temperature (D). 
 
A BA B
C D
+ Anti-ERp57 @ 40oC
+ Anti-ERp57 @ 32oC
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 As previously mentioned, Kras is farnesylated but contains a different second signal 
sequence from Hras for targeting the protein to the plasma membrane and does not traffic to the 
plasma membrane through the secretory pathway.  Because ERp57 specifically recognizes 
farnesylated Hras, it was of interest to determine whether ERp57 played a role in Kras traffic as 
well.  This would be allowed to happen if, for example, ERp57 had a role in transporting ras 
proteins between various ER enzymes that were involved in their post-translational modification.  
This idea was tested using the same peptide carrier technology as described above.  ERp57 
antibodies were transfected into 3T3 cells stably expressing Kras-GFP.  Co-transfection with 
Texas-Red conjugated anti-mouse IgG was used to monitor transfection of the antibody into 
individual cells.  Texas-Red positive cells were then examined by fluorescent microscopy to 
determine the effect on the localization of the Kras-GFP.  The results shown in Figure 11 
indicate that the transfection of Kras-GFP cells with ERp57 antibodies had no affect on the 
plasma membrane localization of Kras.   
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Figure 11: Anti-ERp57 Antibodies Do Not Affect Kras Traffic to the Plasma Membrane.  3T3 
cells stably expressing Kras-GFP (A) were transfected with Texas-Red mouse IgG as a marker 
for transfection (B) and with anti-ERp57 antibodies (C).  The red cells were then examined for 
the localization of the green Kras-GFP by fluorescence microscopy followed by digital 
deconvolution of the acquired images.  Shown is a representative cell of several experiments.  
This experiment shows that blocking ERp57 function has no impact in Kras plasma membrane 
localization. 
 
 
This is consistent also with the hypothesis that Hras and Kras traffic to the plasma membrane via 
different routes.  Together with the results shown in Figure 9, these data strongly suggest a role 
for ERp57 in the specific targeting of Hras to the plasma membrane.  This also suggests that 
although ERp57 recognizes the farnesylated Hras, ERp57 must interact with Hras somewhere 
within the secretory pathway because Kras is farnesylated as well, but ERp57 antibodies do not 
affect its trafficking.  This result is consistent with our previous result shown in figure 5B, that 
Kras and ERp57 do not interact as shown by co-immunoprecipitation and ligand blot. 
A B CControl + Anti-ERp57 
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CHAPTER 4 
DISCUSSSION 
 Previous studies reported from Siddiqui et al. suggested the “two site” hypothesis, where 
partner proteins specifically bind to prenylated proteins through the recognition of both the lipid 
substituents and the primary sequence of the prenylated protein partner (Siddiqui et al. 1998; 
Sinensky 2000b).  The present study was motivated by this hypothesis, and supported by 
previous data, that post-translational lipidation of proteins serves to mediate heterodimeric 
protein-protein interactions (Rusinol et al. manuscript under revision).   
 Consistent with the “two-site” hypothesis, the current study describes a functional partner 
for Hras.  ERp57 has been identified as the heterodimer for Hras because of its ability to bind 
farnesylated Hras relative to non-farnesylated Hras by ligand blotting.  Data from previous work 
have shown that Hras and ERp57 interact in vitro, but do not prove that the 2 proteins associate 
in vivo in 3T3 cells or HeLa cells (Rusinol et al manuscript under revision).  The results of the 
co-immunoprecipitation experiments in this study (Figure 5), where the anti-Hras antibody 
precipitated ERp57, indicate that ERp57 and ras do interact in vivo in 3T3 cells.   The siRNA 
experiments also indicate that there is a connection between ERp57 and ras localization because 
the reduction of cellular levels of ERp57 hindered the localization of Hras at the plasma 
membrane in Hras-GFP cells.  This suggests that ERp57 may also be required for the correct 
folding of another protein that targets Hras. 
 Hras has been proven to traffic from the ER to the plasma membrane using the secretory 
pathway (Choy et al. 1999; Apolloni et al. 2000).  The blockage of Hras trafficking by anti-
ERp57 antibodies can be observed in vitro and in vivo.  The specificity of this interaction was 
confirmed in respect to VSVG protein.  The results of this experiment argue against the blockage 
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of Hras trafficking being a consequence of a global inhibition of the secretory pathway.  Many 
laboratories have demonstrated that Hras plasma membrane localization is dependent on 
farnesylation (Willumsen et al. 1984; Cox et al. 1995).  Other studies have also shown that 
mutations present in the hypervariable region of Hras do not affect its lipidation but do prevent 
correct targeting to the plasma membrane (Willumsen et al. 1996; Jaumot et al. 2002).  However, 
based on our current study we cannot eliminate the possibility that the acyl group of Hras is the 
second recognition site for ERp57. 
 Our observations suggest a binding protein that mediates Hras trafficking, ERp57, that 
recognizes both the lipid moiety and possibly another structural element of Hras.  The specificity 
for inhibition of Hras trafficking relative to Kras trafficking by ERp57 antibodies supports these 
observations.  The CAAX box of Hras and Kras are both sequentially modified in the same 
manner; however, farnesylation alone is not sufficient enough to target the proteins to the plasma 
membrane.  Hras and Kras both must ultimately arrive at the plasma membrane for function, but 
how they reach this final destination is very different from each other.  It is believed that the 
second signal sequence in the hypervariable region, palmitoylation for Hras and Nras or the 
polybasic domain for Kras, serves as a sorting signal that specifies which pathway for the protein 
to take (Hancock et al. 1990; Apolloni et al. 2000).  Although Hras and Kras have many 
similarities, Kras is known to traffic by a different mechanism from Hras (Thissen et al. 1997; 
Apolloni et al. 2000; Chen et al. 2000).  Thus, we have demonstrated that the specificity for Hras 
trafficking on ERp57 compared to VSVG and Kras are consistent with the functional role of 
ERp57 as a chaperone molecule for Hras trafficking operating through the “two-site” recognition 
mechanism (Rusinol et al. manuscript under revision).   
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 ERp57 has been shown to associate with other molecular chaperones such as, calnexin 
and calreticulin, this occurs in the lumen of the ER (Zapun et al. 1998).  It has also been reported 
that ERp57 is associated with the plasma membrane lipid rafts (Guo et al. 2002).  The lipid rafts 
present in the plasma membrane of cells have also been shown as an anchoring point for Hras in 
the plasma membrane (Prior et al. 2001).  The interaction of ERp57 and Hras would not be 
expected to occur in the lumen of the ER because the CAAX processing and plasma membrane 
targeting of Hras takes place on the cytoplasmic side of the ER.  This was demonstrated in the 
present study by the trafficking of full-length Hras and the C-terminal 21 a.a. of Hras was 
blocked by the delivery of anti-ERp57 antibodies into the cytosol of 3T3 cells.  This suggests 
that the site of Hras-ERp57 interaction is located on the cytoplasmic side of the ER/Golgi or the 
cytosol (Rusinol et al. manuscript under revision).   
 The mechanism by which ERp57 participates in Hras traffic is not obvious from the 
present study.  However, because the ERp57 antibodies do not interfere with the trafficking of 
Kras, it is unlikely that ERp57 has a role in CAAX processing.  Therefore, it would be expected 
that ERp57 plays a role in the vesicular trafficking in the secretory pathway, but this also is 
unlikely because of the lack of effect of ERp57 antibodies on the trafficking of VSVG protein.  
Instead, the specificity of inhibition of Hras trafficking compared to that of Kras and VSVG by 
ERp57 antibodies indicates that ERp57 acts at one or more biochemically distinct steps in the 
Hras trafficking pathway (Rusinol et al. manuscript under revision). Given the steps that Kras 
and VSVG have in common with Hras trafficking, the possible site of action for ERp57 should 
occur after CAAX box processing and before entry into the secretory pathway at the Golgi.  Hras 
trafficking through the secretory pathway requires CAAX processing and palmitoylation, to 
allow for the specific targeting of Hras to the caveolin-enriched plasma membrane microdomains 
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(Li et al. 1996).  In contrast, Kras traffics to the plasma membrane using a different route, which 
as we show does not require ERp57 function, and associates with the non-caveolin regions of the 
plasma membrane (Choy et al. 1999; Roy et al. 1999; Apolloni et al. 2000).  However, because 
ERp57 has been proven to interact with lipid rafts in the plasma membrane (Guo et al. 2002) we 
are able to speculate the possibility that ERp57 could mediate the final destination of Hras to the 
caveolin-enriched plasma membrane microdomains (Rusinol et al. manuscript under revision).  
The mechanism by which ERp57 participates in Hras function can possibly defined by the 
isolation and characterization of the large vesicles that contain Hras and are known to 
accumulate upon ERp57 inhibition (Rusinol et al. manuscript under revision).           
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Figure 12:  Model of Ras Trafficking with Potential Erp57 Interaction Sites.  Based on our 
observations the potential sites for ERp57 to interact with Hras have been added to the ras trafficking
model.  Adapted from Apolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF.  H-ras but not K-ras 
traffics to the plasma membrane through the exocytic pathway.  Mol Cell Biol. 2000 Apr; 20(7): 2475-
87.  
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APPENDIX 
LIST OF ABBREVIATIONS 
 
a.a.   amino acid 
BSA   bovine serum albumin 
bp   base pair 
DNA   deoxyribonucleic acid 
DMEM  Dulbecco’s Minimal Essential Medium 
dsRNA  double-stranded RNA  
ER   endoplasmic reticulum 
FBS   fetal bovine serum 
FITC   fluorescein isothiocyanate 
FTase   farnesyl transferase 
GAP   GTPase activating protein 
GDP   guanine diphosphate 
GTP   guanine triphosphate 
HrasCT   Hras 21aa C-terminal fragment 
IgG   immunoglobulin G 
IP   immunoprecipitate 
Kb   kilobase 
kDa   kilodaltons 
mRNA   messenger RNA 
oligo   oligonucleotide 
PalmTase  palmitoyl transferase 
PBS   phosphate buffered saline 
pcCMT  prenylcysteine carboxymethyltransferase 
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PDI   protein disulfide isomerase 
PMCA ATPase Calcium pump of the plasma membrane 
PVDF   polyvinylidene fluoride 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
SAM   S-adenosyl methionine 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA   small interfering RNA 
TCL   total cell lysate 
tsVSVG  temperature sensitive vesicular stomatitis virus glycoprotein 
VSVG   vesicular stomatitis virus glycoprotein  
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